ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2547

Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

Cecilia Stumpf1, Vanessa Rodriguez1 and Carla Cuda2, 1Northwestern University, Chicago, 2Northwestern University, Chicago, IL

Meeting: ACR Convergence 2024

Keywords: interferon, macrophages, Mouse Models, Lupus, neuropsychiatric disorders, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: SLE – Animal Models

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity and mortality among SLE patients, mechanisms driving NPSLE remain poorly understood. Prior work implicates uncontrolled MyD88-dependent toll-like receptor (TLR) activation, increased interferon regulatory factor 5 (IRF5) activity and elevated type I interferon (IFN) levels in peripheral SLE and SLE-like disease. Immune complexes containing self-nucleic acids can aberrantly activate endosomal TLRs 7/8/9, which require signaling adaptor MyD88 to modulate downstream gene expression through transcription factor 1) IRF7 to upregulate IFN, which can subsequently act on the IFN-alpha/beta receptor (IFNAR) or 2) IRF5 to upregulate proinflammatory genes. These cascades result in an inflammatory state throughout the body that is characteristic of SLE. However, it has not yet been shown whether these same pathways are driving inflammation in the brain.

Methods: SLE-and NPSLE-prone CReCOM mice were used, where a conditional deletion of caspase8 in dendritic cells and tissue resident-macrophages leads to development of disease. Conditional deletion of signaling mediators MyD88, IRF5, and IFNAR was introduced into the CReCOM strain. At 3-4 months of age, behavioral phenotypes were assessed by the Rotarod test of coordination and the Morris Water Maze test of memory. At 8-10 months of age, spleens, kidneys, and cervical lymph nodes were collected to assess peripheral disease. Perfused brains were extracted following intravenous labelling for CD45 to exclude remaining circulating immune cells, dural meninges were removed, and cells were analyzed by flow cytometric methods to quantify immune cell populations in the brain.

Results: Conditional deletion of MyD88 and IRF5 ameliorated peripheral disease phenotypes including splenomegaly, lymphadenopathy, and glomerulonephritis, but NPSLE-associated phenotypes in the brain, including expansion of extravascular T and B cells, macrophages, and microglia persisted. In contrast, IFNAR deletion worsened peripheral disease, yet reversed several NPSLE-associated phenotypes. Notably, an important subpopulation of microglia associated with neurodegenerative disease called disease-associated microglia (DAM), characteristically expanded in NPSLE models, remained elevated with MyD88 deletion, but was reduced to near healthy levels with IRF5 and IFNAR deletion. Correspondingly, conditional deletion of IRF5 and IFNAR improved behavior from CReCOM levels, while deletion of MyD88 increased severity of behavioral deficits.

Conclusion: These discoveries suggest an uncoupling of mechanisms driving peripheral and neurological disease. Namely, neurophysiological phenotypes manifest independently from the TLR-dependent pathway that drives peripheral disease and appear to be heavily impacted by the activity of DAM via mechanisms yet unexplored.


Disclosures: C. Stumpf: None; V. Rodriguez: None; C. Cuda: None.

To cite this abstract in AMA style:

Stumpf C, Rodriguez V, Cuda C. Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/neurophysiological-phenotypes-are-uncoupled-from-toll-like-receptor-mediated-peripheral-disease-in-a-mouse-model-of-neuropsychiatric-symptoms-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neurophysiological-phenotypes-are-uncoupled-from-toll-like-receptor-mediated-peripheral-disease-in-a-mouse-model-of-neuropsychiatric-symptoms-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology